ALGS
BEARISH
$7.57
Live
Aligos Therapeutics, Inc. · NASDAQ
Target $68.2
(+800.9%)
$3.76
52W Range
$13.69
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$46.58M
P/E
N/A
ROE
-196.9%
Profit margin
N/A
Debt/Equity
0.1
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ALGS exhibits severe financial distress, reflected in a Piotroski F-Score of 0/9 and a lack of Altman Z-Score, indicating extreme bankruptcy risk. The company reports massive negative profitability metrics, including a -12,907.69% operating margin and -196.91% ROE, alongside a 73.1% YoY revenue decline. Despite a strong analyst consensus of 'strong_buy' and a high target price of $80.25, the stock trades at a premium valuation (Price/Sales of 21.31) with no earnings or cash flow generation. Insider sentiment is neutral, and technical trends are bearish, underscoring a lack of market confidence. The combination of deteriorating fundamentals and speculative valuation creates a high-risk profile.
Key Strengths
Analyst consensus is strongly bullish with a $80.25 target price
Recent quarterly EPS growth shows strong momentum (+85.4% YoY, +37.2% Q/Q)
Positive earnings surprises in 2 of the last 4 quarters (average +3.87%)
High insider sentiment (40/100) suggests some confidence among insiders
Strong current and quick ratios (3.90 and 3.67) indicate short-term liquidity
Key Risks
Piotroski F-Score of 0/9 signals extreme financial distress and operational failure
Negative operating margin (-12,907.69%) and ROE (-196.91%) reflect deep unprofitability
73.1% YoY revenue decline indicates business contraction
No cash flow or free cash flow data available, raising liquidity concerns
Price/Sales of 21.31 is extremely high for a company with no earnings or growth
No Graham Number or intrinsic value estimate, indicating no defensive valuation floor
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
10
60
20
10
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 0/9, Negative profitability and revenue decline, Lack of Altman Z-Score (implied distress risk), High valuation relative to fundamentals, No cash flow or earnings generation
Confidence
85%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.87 suggests potential undervaluation on asset basis
Watchpoints
- Price/Sales of 21.31 is extremely high for a non-profitable company
- No Graham Number or intrinsic value estimate available
- No earnings to support valuation metrics
- Trading at premium despite negative fundamentals
Future
60/100
Ref Growth rates
Positives
- Strong YoY and Q/Q EPS growth (+85.4% and +37.2%)
- Recent positive earnings surprises in 2 of last 4 quarters
- Analyst target price of $80.25 implies high growth expectations
Watchpoints
- 73.1% YoY revenue decline contradicts growth narrative
- No forward earnings or cash flow data available
- High growth expectations are not supported by current financials
Past
20/100
Ref Historical trends
Positives
- Consistent earnings reporting over 23 quarters
- Some quarters show significant positive surprises (e.g., +262.4%)
Watchpoints
- Most recent quarters show large negative surprises (e.g., -256.9%)
- Revenue and earnings have been declining for multiple periods
- Operating margin has deteriorated to extreme levels
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 3.90 and quick ratio of 3.67 indicate strong short-term liquidity
- Debt/Equity of 0.10 suggests low leverage
Watchpoints
- Piotroski F-Score of 0/9 indicates complete financial deterioration
- No Altman Z-Score available, but F-Score of 0 implies distress risk
- Negative ROE and ROA indicate capital destruction
- No operating cash flow or free cash flow data
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
- Company is not generating profits to support dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.57
Analyst Target
$68.2
Upside/Downside
+800.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALGS and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALGS
Aligos Therapeutics, Inc.
Primary
|
-98.8% | -77.7% | -26.4% | -25.8% | +1.5% | +8.4% |
|
IMMP
Immutep Limited
Peer
|
-91.1% | -80.6% | -78.0% | -84.6% | -88.8% | -13.9% |
|
ONMD
OneMedNet Corporation
Peer
|
-91.1% | -91.8% | +65.5% | -68.2% | +9.7% | +2.6% |
|
POM
Pomdoctor Limited
Peer
|
-90.5% | -90.5% | -90.5% | -91.4% | -7.3% | +17.2% |
|
RNXT
RenovoRx, Inc.
Peer
|
-86.2% | -68.2% | -2.0% | -10.7% | -2.9% | +1.5% |
ALG
Aligos Therapeutics, Inc.
Primary
5Y
-98.8%
3Y
-77.7%
1Y
-26.4%
6M
-25.8%
1M
+1.5%
1W
+8.4%
IMM
Immutep Limited
Peer
5Y
-91.1%
3Y
-80.6%
1Y
-78.0%
6M
-84.6%
1M
-88.8%
1W
-13.9%
ONM
OneMedNet Corporation
Peer
5Y
-91.1%
3Y
-91.8%
1Y
+65.5%
6M
-68.2%
1M
+9.7%
1W
+2.6%
POM
Pomdoctor Limited
Peer
5Y
-90.5%
3Y
-90.5%
1Y
-90.5%
6M
-91.4%
1M
-7.3%
1W
+17.2%
RNX
RenovoRx, Inc.
Peer
5Y
-86.2%
3Y
-68.2%
1Y
-2.0%
6M
-10.7%
1M
-2.9%
1W
+1.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.42
PEG Ratio
N/A
P/B Ratio
0.87
P/S Ratio
21.31
EV/Revenue
-11.78
EV/EBITDA
0.3
Market Cap
$46.58M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-12907.7%
Gross Margin
N/A
ROE
-196.91%
ROA
-69.33%
Growth
Revenue and earnings growth rates
Revenue Growth
-73.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.1
Low debt
Current Ratio
3.9
Strong
Quick Ratio
3.67
Excellent
Cash/Share
$12.58
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-03-05
$-1.91
+23.2% surprise
2025-11-06
$-3.04
-51.2% surprise
2025-08-06
$-1.53
+39.6% surprise
Healthcare Sector Comparison
Comparing ALGS against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-196.91%
This Stock
vs
-88.14%
Sector Avg
+123.4%
(Excellent)
Debt to Equity
0.1
This Stock
vs
2.66
Sector Avg
-96.3%
(Less Debt)
Revenue Growth
-73.1%
This Stock
vs
124.04%
Sector Avg
-158.9%
(Slower)
Current Ratio
3.9
This Stock
vs
4.47
Sector Avg
-12.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALGS
Aligos Therapeutics, Inc.
|
BEARISH | $46.58M | - | -196.9% | -% | $7.57 | |
|
IMMP
Immutep Limited
|
BEARISH | $46.14M | - | -61.8% | -% | $0.31 | Compare |
|
ONMD
OneMedNet Corporation
|
BEARISH | $46.04M | - | -% | -206.1% | $0.88 | Compare |
|
POM
Pomdoctor Limited
|
BEARISH | $45.43M | - | -% | -40.6% | $0.38 | Compare |
|
RNXT
RenovoRx, Inc.
|
BEARISH | $45.05M | - | -225.6% | -% | $1.0 | Compare |
ALGS
Aligos Therapeutics, Inc.
BEARISH
Mkt Cap
$47M
P/E
-
ROE
-196.9%
Price
$7.57
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
HC Wainwright & Co.
2026-03-11
Buy
Buy
UBS
2026-01-07
Buy
Past News Coverage
Recent headlines mentioning ALGS from our newsroom.
Newest → oldest
No matching news yet.